Emergent BioSolutions | EBS - Stock


Emergent BioSolutions reported $328.9M in Stock for its fiscal quarter ending in December of 2023.





Stock Change Date
Acadia Pharmaceuticals USD 108.67M 77.1M Jun/2026
Akebia Therapeutics USD 13M 2.61M Mar/2026
ALKERMES USD 298.96M 37.75M Jun/2026
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
Amarin USD 164.07M 19.51M Jun/2026
ANI Pharmaceuticals USD 143.47M 401K Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Coherus Biosciences USD 3.17M 1.12M Dec/2025
Emergent BioSolutions USD 328.9M 25.2M Dec/2023
Exelixis USD 26.6M 4.92M Mar/2026
Glaxosmithkline GBP 6.16B 39M Mar/2026
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Ionis Pharmaceuticals USD 50.83M 45.28M Jun/2026
Lexicon Pharmaceuticals USD 276K 5K Mar/2026
Lonza CHF 1.68B 163M Dec/2025
Merck USD 6.48B 179M Mar/2026
Moderna USD 280M 134M Jun/2026
Myriad Genetics USD 30.6M 2.7M Jun/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 104.2M 39.7M Jun/2026
Pacira USD 134.57M 15.8M Jun/2026
Pfizer USD 9.94B 722M Jun/2026
PTC Therapeutics USD 91.35M 15.79M Jun/2026
Sanofi EUR 24.12B 620M Jun/2026
Sarepta Therapeutics USD 1B 86.37M Mar/2026
United Therapeutics USD 193.8M 15.5M Jun/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025